| The splicing factor FUBP1 is required for the efficient splicing of oncogene MDM2 pre-mRNA. | None |
| Similar to oncoproteins that induce a DNA damage response and oncogene induced senescence in non-transformed cells, MDM2 induces G1-arrest and intra-S phase checkpoint responses that control untimely DNA replication | None |
| MDM2 overexpression, activation of signaling networks, and cell proliferation. | None |
| Dysregulation of p53-independent functions could be responsible for oncogenic properties of Mdm2 seen even in the absence of p53, and may explain why approximately 10 % of human tumors overexpress Mdm2 instead of inactivating p53 through other mechanisms | None |
| Autoinhibition of MDMX by intramolecular p53 mimicry. | None |
| Structure- and ligand-based virtual screening identifies new scaffolds for inhibitors of the oncoprotein MDM2. | None |
| Mdm2 overexpression and p73 loss cooperate in genomic instability and tumor development, indicating that the oncogenic function of Mdm2 is a combined effect of inhibiting p53 and p73 functions | None |
| Synthetic Proteins Potently and Selectively Bind the Oncoprotein Gankyrin, Modulate Its Interaction with S6 ATPase, and Suppress Gankyrin/MDM2-Dependent Ubiquitination of p53. | None |
| Elucidation of Ligand-Dependent Modulation of Disorder-Order Transitions in the Oncoprotein MDM2. | None |
| Findings indicate molecular simulations of c-mdm2 proto-oncogene protein (MDM2) and its complex with tumor suppressor protein p53 (p53) by explicit-solvent simulations. | None |
| Data show that proto-oncogene protein Mdm2 inactivation successfully protects tumor suppressor protein (p53)-proficient cells against the cytotoxic effects of Wee1 protein inhibition. | None |
| Data show that TTK protein kinase (hMps1) interacts with proto-oncogene protein MDM2 in vivo and in vitro. | None |
| Data show that the c-mdm2 proto-oncogene protein (MDM2) single nucleotide polymorphism SNP309 T/T allele indicated a significant contribution to age at time of surgery. | None |
| findings document contrasting effects of ATM-Mdm2 signaling on p53 tumor suppression and reveal that destabilizing Mdm2 by promoting its phosphorylation by ATM would be effective in treating oncogene-induced malignancies. | None |
| Results suggest that microRNA miRNA-509-5p negatively regulates c-mdm2 proto-oncogene protein (MDM2) expression via targeting the 3_ untranslated region (3_-UTR) of genes. | None |
| Homeobox A13 (HOXA13) played a role of carcinogenesis through directly down-regulating dehydrogenase/reductase 2 (DHRS2) to increase proto-oncogene proteins c-mdm2 (MDM2). | None |
| Spindlin 1 (SPIN1) sequesters ribosomal protein uL18 in the nucleolus, preventing it from interacting with c-mdm2 Proto-oncogene protein (MDM2), and alleviating uL18-mediated inhibition of MDM2 ubiquitin ligase activity toward p53 tumor suppressor protein (p53). | None |
| Overexpression of Mdm2 corrected age-related bone loss in mice, providing a role for the proto-oncogenic activity of Mdm2 in bone health of adult animals. | None |
| MDM2_s dual mRNA binding domains co-ordinate its oncogenic and tumour suppressor activities. | None |
| Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. | None |